Biophytis (BPTSY) launches Hong Kong JV for BIO101 with up to $20M backing
Rhea-AI Filing Summary
Biophytis SA has officially registered its Hong Kong joint venture, Biophytis Biopharmaceutical Group Limited, a key step in its Asia strategy. The new entity will develop and commercialize BIO101, particularly for treating sarcopenia, and support clinical programs in Asian markets.
Operational closing will include the transfer of Biophytis’ intellectual property to the joint venture and a first investment tranche of $3 million from Asian partners. Total secured funding can reach up to $20 million over three years, enabling trial preparation, regulatory submissions, site openings in China and Japan, and team recruitment. The joint venture is expected to be operational starting in July 2026.
Positive
- Funded Asian expansion for BIO101: The Hong Kong joint venture comes with a first investment tranche of $3 million and total secured funding of up to $20 million over three years to support BIO101 clinical and commercial development in Asia.
Negative
- None.
Insights
Biophytis secures funded Asia JV to drive BIO101 development.
Biophytis has formally established a Hong Kong joint venture to develop and commercialize BIO101 in Asia, focused on sarcopenia. This structure anchors its previously announced Asian partnership in a dedicated vehicle with regional execution responsibility.
The agreement links staged funding to clinical development, with a first $3 million tranche at operational closing and total secured funding of up to $20 million over three years. This provides non‑U.S., non‑European capital support for BIO101, which is described as Phase 3 ready in sarcopenia and Phase 2 ready in obesity.
The filing states the joint venture should be operational from July 2026, enabling preparatory work, regulatory submissions, and site activation in China and Japan. Subsequent disclosures on trial initiation, patient enrollment, and further tranche releases tied to development milestones will clarify how effectively this structure accelerates BIO101 in Asian markets.
Key Figures
Key Terms
joint venture financial
sarcopenia medical
Phase 3 medical
Phase 2 medical
clinical-stage biotechnology company financial
UNITED STATES SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Date of report: June 9, 2026
Commission File Number: 001-38974
BIOPHYTIS S.A.
(Translation of registrant’s name into English)
Stanislas Veillet
Biophytis S.A.
Sorbonne University—BC 9, Bâtiment A 4ème étage
4 place Jussieu
75005 Paris, France
+33 1 44 27 23 00
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
x Form 20-F ¨ Form 40-F
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
On June 9, 2026, Biophytis S.A. issued a press release announcing the official registration of its joint venture in Asia. A copy of the press release is attached as Exhibit 99.1 to this Form 6-K.
EXHIBIT LIST
| Exhibit | Description | |
| 99.1 | Press Release dated June 9, 2026. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| BIOPHYTIS S.A. | ||
| Date: June 9, 2026 | By: | /s/ Stanislas Veillet |
| Name: Stanislas Veillet | ||
| Title: Chairman and Chief Executive Officer | ||
Exhibit 99.1
New strategic Milestone for Biophytis:
Official Establishment of Its Joint Venture in Asia
Paris (France) and Cambridge (Massachusetts, United States), June 9th, 2026 at 7.00 AM (CET) – Biophytis SA (Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), a pioneer in the development of transformative therapies impacting longevity, today announces the official registration of its joint venture in Hong Kong, Biophytis Biopharmaceutical Group Limited, marking a decisive milestone in the implementation of the strategic partnership in Asia, which was announced on January 28, 2026.
This new entity represents a major step in Biophytis’ international strategy to strengthen its presence in Asia. It will be tasked with developing and commercializing BIO101 in the region, particularly for the treatment of sarcopenia.
Stanislas Veillet, Chairman and CEO of Biophytis, said: “The registration of our joint venture in Hong Kong is an essential milestone in the execution of our strategic agreement in Asia. We are moving with determination toward the operational closing of this operation, which will pave the way for the concrete launch of our clinical program in Asian markets. Our partnership confirms the appeal of BIO101 and strengthens our ability to address the immense unmet medical need represented by sarcopenia, in Asia as well as in Europe.”
Next Steps Toward Operational Launch
The registration of the joint venture clears the way for the operational closing, which will simultaneously include the effective transfer of Biophytis’ intellectual property to the joint venture and the injection of the first investment tranche of $3 million by the Asian partners.
This first tranche of funding will enable the immediate launch of preparatory work for the clinical trial in Asia, the submission of applications for authorization to begin the trial, the opening of clinical centers in China and Japan, and the recruitment of the management team. The joint venture will be operational starting in July 2026. As a reminder, the total secured funding amounts to up to $20 million over three years, disbursed in stages based on clinical development, in accordance with the agreement announced in January 2026.
***
About BIOPHYTIS
Biophytis SA is a clinical-stage biotechnology company focused on developing drug candidates for age-related diseases. BIO101 (20-hydroxyecdysone), our lead drug candidate, is a small molecule in development for muscular diseases (sarcopenia, Phase 3 ready to start) and metabolic disorders (obesity, Phase 2 ready to start). The company is headquartered in Paris, France, with subsidiaries in Cambridge, Massachusetts, USA, and Brazil. The Company’s ordinary shares are listed on Euronext Growth Paris (ALBPS - FR001400OLP5) and its ADS (American Depositary Shares) are listed on the OTC market (BPTSY - US 09076G401). For more information, visit www.biophytis.com.
Biophytis Contacts
Investor Relations
investors@biophytis.com
Media contacts
Antoine Denry: antoine.denry@taddeo.fr – +33 6 18 07 83 27
Nizar Berrada: nizar.berrada@taddeo.fr – +33 6 38 31 90 50